Skip to main content
3D Medicines Inc. logo

3D Medicines Inc. — Investor Relations & Filings

Ticker · 1244 ISIN · KYG8872R1011 HKEX Manufacturing
Open in API
Filings indexed 144 across all filing types
Latest filing 2026-05-21 Regulatory Filings
Country HK Hong Kong
Listing HKEX 1244

About 3D Medicines Inc.

https://www.3d-medicines.com

3D Medicines Inc. is an oncology-focused, commercial-stage biopharmaceutical company specializing in the development and commercialization of next-generation immuno-oncology therapies. The company leverages global research and development capabilities and internal discovery platforms to advance a pipeline of innovative drug candidates. Its core mission is to address unmet medical needs in cancer treatment, aiming to transform cancer into a chronic disease and provide substantial value to patients and healthcare providers globally.

Recent filings

Filing Released Lang Actions
VOLUNTARY ANNOUNCEMENT EARLY COMPLETION OF ENROLLMENT IN THE PHASE III CLINICAL TRIAL OF ENVAFOLIMAB FOR NEOADJUVANT/ADJUVANT TREATMENT OF NON-SMALL CELL LUNG CANCER
Regulatory Filings Classification · 85% confidence The document is a voluntary announcement regarding the early completion of patient enrollment in a Phase III clinical trial. It does not contain any financial statements, securities transactions, voting results, or formal report attachments; instead it is a general business update filed on an exchange. This falls under the broad “Regulatory Filings” category for miscellaneous announcements that do not match more specific categories.
2026-05-21 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2026
Regulatory Filings Classification · 95% confidence The document is a monthly return report submitted to the Hong Kong Exchanges and Clearing Limited (HKEX) regarding movements in securities for the issuer 3D Medicines Inc. It details movements in authorized share capital, issued shares, treasury shares, share options, and public float sufficiency confirmation for the month ended 30 April 2026. The document is a regulatory compliance filing related to share capital and securities movements, not a financial report, earnings release, or management discussion. It is a routine regulatory submission under HKEX Listing Rules Chapter 19B, providing detailed share capital and securities movement data. This type of document fits best under Regulatory Filings (RNS) as it is a general regulatory announcement and does not match other more specific categories like capital changes (SHA) or director dealings (DIRS) since it is a monthly return report rather than a specific transaction or announcement. The document length (9560 characters) and content confirm it is a substantive regulatory filing rather than a brief announcement or report publication notice.
2026-05-06 English
Annual Report 2025
Annual Report Classification · 100% confidence The document is titled 'Annual Report 2025' and contains detailed sections typical of a full annual report, including Chairman's Statement, Financial Summary, Management Discussion and Analysis, Biographies of Directors and Senior Management, Corporate Governance Report, Report of Directors, Environmental, Social and Governance Report, Independent Auditor's Report, and full consolidated financial statements with notes. The presence of comprehensive financial data and extensive narrative confirms this is the full annual report for the fiscal year ended December 31, 2025. The document length is 15,000 characters, indicating it is a full report rather than a brief announcement or summary. Therefore, the appropriate classification is Annual Report (10-K).
2026-04-30 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2026
Regulatory Filings Classification · 95% confidence The document is a standard monthly return (Form FF301) filed with the Hong Kong Exchange listing office under Chapter 19B of the Listing Rules. It provides detailed movements in authorised/issued share capital, share options, public float sufficiency, and confirmations required by listing rules. It is neither an earnings announcement nor an annual/interim report, nor a specific share issuance event, nor a management change, but a routine regulatory compliance submission. Therefore it falls under the general “Regulatory Filings” category.
2026-04-02 English
DISCLOSEABLE TRANSACTION; AND CLARIFICATION ANNOUNCEMENT ON THE ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2025
Capital/Financing Update Classification · 90% confidence The document is a Hong Kong Exchange announcement under the Listing Rules (Chapter 14) detailing a discloseable transaction: the extension of a short-term note by the company, including the transaction background, terms, Listing Rules implications, and remedial measures for a disclosure breach. This falls squarely under updates on financing activities or capital structure changes. Although it also includes a clarification on the prior annual results announcement, the primary purpose is to disclose the financing transaction. Therefore, the appropriate category is a Capital/Financing Update.
2026-04-01 English
ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2025
Earnings Release Classification · 85% confidence The document is an “Annual Results Announcement” covering the financial performance for the year ended December 31, 2025. It provides business highlights, summarized financial tables, IFRS measures and MD&A. While it is comprehensive, it is clearly an earnings‐styled release of annual results rather than the full statutory annual report with complete notes and auditor’s opinion sections. This matches the definition of an Earnings Release (ER). FY 2025
2026-03-31 English

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.